Bitcoin set for a rebound that could stretch toward $100000, BTIG says
DUBLIN - Investment giant BlackRock, Inc. has disclosed a 6.89% stake in Avadel Pharmaceuticals plc, according to a regulatory filing published Monday.
The disclosure, made under Irish Takeover Panel rules, shows BlackRock holds 6,732,406 ordinary shares in the pharmaceutical company as of November 21, 2025. The filing also reveals a minimal short position of 3,806 shares through cash-settled derivatives, representing less than 0.01% of the company.
The filing details recent transactions including a purchase of 3,043 shares at $23.03 per unit, the return of 198,100 shares that were on loan, and the transfer in of 5,888 shares.
The disclosure was made in compliance with Rule 8.3 of the Irish Takeover Panel Act, which requires persons with interests in relevant securities representing 1% or more to disclose their positions.
BlackRock, one of the world’s largest asset managers, made the disclosure as an opening position statement, suggesting potential takeover activity involving Avadel Pharmaceuticals, though no specific offer details were mentioned in the filing.
Avadel Pharmaceuticals, which trades on the Nasdaq, specializes in pharmaceutical products. The company has not issued any statements regarding potential acquisition interest based on the information in the press release.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.